Early Life
Thomas Strüngmann was born in 1950. He earned a Master of Business Administration from the University of Augsburg. He started his career as a marketing manager at Schering-Plough.
Rise to Success
In 1979, Thomas and his twin brother, Andreas, took over their father's pharmaceutical company, Durachemie, gaining valuable industry experience. In 1986, they co-founded Hexal AG, focusing on generic pharmaceuticals, and it became one of Germany's leading generic drug manufacturers. Under the leadership of Thomas and Andreas, Hexal achieved significant success. In 2005, they sold Hexal and their stake in Eon Labs to Novartis for approximately $7.5 billion. The Strüngmann brothers were early backers of BioNTech, which partnered with Pfizer to make a vaccine for Covid-19. Their investment in BioNTech played a crucial role in the development of a COVID-19 vaccine in partnership with Pfizer, marking a significant achievement in the fight against the pandemic. The brothers earned $8 billion on their stake in BioNTech.
Key Business Strategies
The Strüngmann brothers have focused on innovation, long-term investment, and improving global healthcare, which has been the foundation of their financial success. They invest in various biotech, pharmaceutical, life sciences, and healthcare companies through their investment firm, Santo Holding.
Philanthropy
In 2008, the Strüngmann brothers established a neuroscience research center in Frankfurt, named after their father, Ernst Strüngmann.